Author:
Morgan Lee Roy,Struck Robert F.,Waud William R.,LeBlanc Blaise,Rodgers Andrew H.,Jursic Branko S.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference20 articles.
1. Berlin J, Stewart JA, Storer B, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Simon K, Wilding G (1998) Phase I clinical and pharmacokinetic trial of penclomedine using a novel, two stage trial design for patients with advanced malignancy. J Clin Oncol 16:1142–1149
2. O’Reilly S, Grochow L, Donehower RC, Bowling K, Chen TL, Hartman N, Struck R, Rowinsky EK (1997) Phase I and pharmacologic studies of penclomedine, a novel alkylating agent in patients with solid tumors. J Clin Oncol 15:1974–1984
3. Jodrell DI, Bowman A, Stewart M, Dunlop N, French R, MacLellan A, Cummings J, Smyth JF (1998) Dose-limiting neurotoxicity in a phase I study of penclomedine (NSC 388720, CRC 88-04), a synthetic alpha-picoline derivative, administered intravenously. Br J Cancer 77:808–811
4. Berlin J, Wahamaki A, Tutsch KD, Alberti D, Feierabend C, Binger K, Arzoomanian RZ, Volkman J, Karca J, Mornocha R, Stewart J, Wilding G (1999) Phase I, pharmacokinetic and bioavailability study of oral penclomedine administered daily × 5 every four weeks. Proc Am Assoc Cancer Res 40:92
5. Hartman NR, O’Reilly S, Rowinsky EK, Collins JM, Strong JM (1996) Murine and human in vivo penclomedine metabolism. Clin Cancer Res 2:953–962
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献